3:09
ESH MM 2018 | Frontline transplant-ineligible MM treatment
Kwee Yong
3:48
ESH MM 2018 | Real world evidence: what is it and what can it tell us?
Kwee Yong
2:17
ESH MM 2018 | Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma
Maria-Victoria Mateos
1:56
ESH MM 2018 | How do we define a ‘cure’ in myeloma?
Annemiek Broyl
0:59
ESH MM 2018 | Opinion: MRD sequencing test approval in multiple myeloma
Irene Ghobrial
1:33
iwNHL 2018 | CAR T-cell therapy: on the way to success
Steven Rosen
1:09
iwNHL 2018 | Non-hodgkin lymphoma advances in 2018
Steven Rosen
2:03
iwNHL 2018 | The challenging field of hem-onc therapeutics
Steven Rosen
2:47
SOHO 2018 | Molecular background studies to aid diagnosis and treatment of MDS
Torsten Haferlach
0:55
SOHO 2018 | The unmet needs in low-risk MDS
David Steensma
1:27
EBMT 2018 | Topics of interest from EBMT 2018
Abdul Hamid Bazarbachi
1:49
EBMT 2018 | The use of social media for career development: a physician’s perspective
Khaled Ghanem
2:47
ESH AL 2018 | The need for prompt patient referral and clear informed consent
Oliver Ottmann
3:16
ESH AL 2018 | Clinical approaches in Ph+ and Ph-like ALL
Robin Foà
2:42
ESH AL 2018 | The potential for a chemotherapy-free strategy in ALL
Robin Foà
1:23
ESH AL 2018 | The challenges halting clinical trial progress in ALL
Oliver Ottmann
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals